GlassScriptPhysician profile
Vasudha Aruna Panday
NPI 1982660130
$5,083.91
in general payments reported to CMS, 2019-2025
27 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $133 · 2021: $185 · 2022: $907 · 2023: $536 · 2024: $822 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,028.70 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $800.00 | 2019 | |
| Rxsight INC | $514.08 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $438.16 | 2019-2025 | Cequa |
| Abbvie INC. | $277.57 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $228.67 | 2022-2024 | Tecnis Iol, Tecnis Simplicity, One Series Ultra |
| Bausch & Lomb Americas INC. | $211.43 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $163.52 | 2020-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $154.52 | 2019-2022 | |
| Alcon Vision LLC | $134.48 | 2019-2025 | Hydrus Microstent, Eysuvis, Clareon |
| Oyster Point Pharma, INC. | $130.72 | 2022-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $121.60 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $109.01 | 2022-2025 | Dextenza |
| Ani Pharmaceuticals, INC. | $102.55 | 2022-2023 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $96.03 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $92.32 | 2019-2025 | Oxervate |
| Horizon Therapeutics Plc | $90.07 | 2022-2023 | Tepezza |
| Lensar, INC. | $87.38 | 2025 | Lensar Laser System |
| Glaukos Corporation | $64.28 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Radius Xr |
| Eyevance Pharmaceuticals LLC | $52.33 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $45.47 | 2020-2021 | |
| Sight Sciences, INC. | $39.58 | 2022-2025 | Tearcare System |
| Mallinckrodt Enterprises LLC | $25.59 | 2019 | |
| Shire North American Group INC | $23.97 | 2019 | |
| Allergan, INC. | $19.83 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.42 | 2019 | |
| Thea Pharma INC. | $15.63 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasudha Panday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.